Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $37

Benzinga · 2d ago
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $42 to $37.